Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Tumor-infiltrating HLA-matched CD4(+) T cells retargeted against Hodgkin and Reed-Sternberg cells.

Rengstl B, Schmid F, Weiser C, Döring C, Heinrich T, Warner K, Becker PS, Wistinghausen R, Kameh-Var S, Werling E, Billmeier A, Seidl C, Hartmann S, Abken H, Küppers R, Hansmann ML, Newrzela S.

Oncoimmunology. 2016 Mar 16;5(6):e1160186. doi: 10.1080/2162402X.2016.1160186. eCollection 2016 Jun.

2.

Immunotherapy: opportunities, risks and future perspectives.

Hildebrandt M, Peggs K, Uharek L, Bollard CM, Heslop HE.

Cytotherapy. 2014 Apr;16(4 Suppl):S120-9. doi: 10.1016/j.jcyt.2014.02.001. Review.

3.

Hodgkin lymphoma.

Küppers R, Engert A, Hansmann ML.

J Clin Invest. 2012 Oct;122(10):3439-47. doi: 10.1172/JCI61245. Epub 2012 Oct 1. Review.

4.

Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications.

de la Cruz-Merino L, Lejeune M, Nogales Fernández E, Henao Carrasco F, Grueso López A, Illescas Vacas A, Pulla MP, Callau C, Álvaro T.

Clin Dev Immunol. 2012;2012:756353. doi: 10.1155/2012/756353. Epub 2012 Aug 15. Review.

5.

EBV-associated lymphomas in adults.

Roschewski M, Wilson WH.

Best Pract Res Clin Haematol. 2012 Mar;25(1):75-89. doi: 10.1016/j.beha.2012.01.005. Epub 2012 Feb 5. Review.

6.

Lymphoma stem cells: A step toward a new therapeutic target.

Kim SJ.

Korean J Hematol. 2011 Dec;46(4):211-3. doi: 10.5045/kjh.2011.46.4.211. Epub 2011 Dec 27. No abstract available.

7.

Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.

Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, Gottschalk SM, Savoldo B, Vera JF, Heslop HE, Brenner MK, Bollard CM, Rooney CM, Leen AM.

Mol Ther. 2011 Dec;19(12):2258-68. doi: 10.1038/mt.2011.167. Epub 2011 Sep 13.

8.

Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM.

Clin Cancer Res. 2011 Nov 15;17(22):7058-66. doi: 10.1158/1078-0432.CCR-11-1873. Epub 2011 Sep 9. Erratum in: Clin Cancer Res. 2012 Feb 1;18(3):913. Dosage error in article text.

9.

Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma.

Bae J, Carrasco R, Lee AH, Prabhala R, Tai YT, Anderson KC, Munshi NC.

Leukemia. 2011 Oct;25(10):1610-9. doi: 10.1038/leu.2011.120. Epub 2011 Jun 10.

10.
11.

Flow cytometric detection of the classical hodgkin lymphoma: clinical and research applications.

Roshal M, Wood BL, Fromm JR.

Adv Hematol. 2011;2011:387034. doi: 10.1155/2011/387034. Epub 2010 Nov 28.

12.

T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications.

Fozza C, Longinotti M.

Adv Hematol. 2011;2011:501659. doi: 10.1155/2011/501659. Epub 2010 Oct 12.

13.

Therapeutic cancer vaccines in combination with conventional therapy.

Andersen MH, Junker N, Ellebaek E, Svane IM, Thor Straten P.

J Biomed Biotechnol. 2010;2010:237623. doi: 10.1155/2010/237623. Epub 2010 Jun 29. Review.

Supplemental Content

Support Center